Mineralys Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $1.77B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 9, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 11, 2026 | After market close | – | $-2.85 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 6, 2026 | After market close | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 12, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 10, 2025 | After market close | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | After market close | – | $-0.66 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 12, 2025 | After market close | – | $-0.79 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 12, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | After market close | – | $-0.83 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | Before market open | – | $-0.70 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 21, 2024 | Before market open | – | $-0.61 | – |
Press releases
Announcements Mineralys Therapeutics filed with the SEC
Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
Other events · EX-99.1 to Form 8-K
Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Mineralys Therapeutics Announces Proposed Public Offering of Common Stock
Other events · EX-99.1 to Form 8-K
Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock
Other events · EX-99.2 to Form 8-K
Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25)
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Mineralys Therapeutics Announces Proposed Public Offering of Common Stock
Other events · EX-99.1 to Form 8-K
Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock
Other events · EX-99.2 to Form 8-K
Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Mineralys Therapeutics Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Material agreement · Results of operations · EX-99.1 to Form 8-K
Mineralys Therapeutics Announces $120 Million Private Placement Financing
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer
Executive or director change · Regulation FD disclosure · EX-99 to Form 8-K
Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Mineralys Therapeutics Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting
Regulation FD disclosure · EX-99.1 to Form 8-K
Mineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Mineralys Therapeutics Announces Expansion of Planned Phase 2 Trial of Lorundrostat Alone and in Combination with SGLT2 Inhibitor to Treat Patients with Chronic Kidney Disease (CKD)
Regulation FD disclosure · EX-99.1 to Form 8-K
Mineralys Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K